volume 29, issue 3, P527-535 2012
DOI: 10.3233/jad-2012-111370
View full text
|
Sign up to set email alerts
|
Share

Abstract: New criteria related to prodromal Alzheimer's disease (AD) have been proposed to overcome the issue of heterogeneity of patients with mild cognitive impairment (MCI) and to better define patients in early stage AD. Only few therapeutic trials, if any, have been reported using this newly defined population. The objective of this study was to assess the clinical efficacy and safety of a novel pro-cholinergic drug (V0191) in patients with prodromal AD. Two hundred forty two (242) patients with a diagnosis of prod…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
1
2

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals